Literature DB >> 10884502

The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard?

A Moreno1, G Colon-Otero, L A Solberg.   

Abstract

PURPOSE: Discrepancies in the quoted prednisone dosages in the regimens reported as the only standard CHOP regimen stimulated our interest in reviewing the medical literature regarding this issue and to assess whether practicing hematologists and oncologists in the U.S. are aware of the different dose schedules of prednisone in the published CHOP programs.
METHODS: Sixteen textbooks and chemotherapy reference books were reviewed. A MEDLINE search of English-language articles published between January 1970 and December 1998 was performed. An eight-point questionnaire was sent via e-mail with responses obtained from 421 hematology/oncology physicians in the U.S.
RESULTS: Sixteen textbooks and chemotherapy reference books reviewed quoted only one prednisone dosage as part of the standard CHOP regimen; the prednisone dosages quoted as standard varied between publications. More than 4,000 eligible non-Hodgkin's lymphoma patients have been treated with the CHOP chemotherapy as part of 43 different clinical trials reviewed. The dosages of prednisone and prednisolone used varied among six different levels. Thirty percent (127/421) of practicing U.S. physicians were not aware of the existence of more than one prednisone dose schedule as part of the CHOP regimen. The three most frequently used dosages are 100 mg/days 1-5 (67%), 100 mg/m(2)/days 1-5 (17%), and 60 mg/m(2)/days 1-5 (13%).
CONCLUSIONS: Discrepancies in steroid dosages used as part of the reported standard CHOP regimens are common and not well recognized in the medical literature nor by practicing U.S. hematologists/oncologists. Based on this study, a prednisone dose of 100 mg/day for five days should be considered the standard dose.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884502     DOI: 10.1634/theoncologist.5-3-238

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  6 in total

Review 1.  Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients.

Authors:  Amy Hiestand; James Flory; Ritika Chitkara
Journal:  Curr Diab Rep       Date:  2019-11-27       Impact factor: 4.810

2.  Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.

Authors:  Zanetta S Lamar; Andrew Dothard; LeAnne Kennedy; Scott Isom; Mac Robinson; Rakhee Vaidya; David Hurd; Donald McClain; Glenn Lesser
Journal:  Leuk Lymphoma       Date:  2017-12-18

Review 3.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

4.  Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy.

Authors:  Katiuscia O'Brian; Suhong Luo; Arun Ganti; Peter Riedell; Ryan C Lynch; Ryan Roop; Kristen M Sanfilippo; Weijian Liu; Graham A Colditz; Kenneth R Carson
Journal:  Leuk Lymphoma       Date:  2015-07-25

5.  High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas.

Authors:  Li-Wen Huang; Dong Sun; Thomas M Link; Thomas Lang; Weiyun Ai; Lawrence D Kaplan; Michael A Steinman; Charalambos Andreadis
Journal:  Support Care Cancer       Date:  2021-03-10       Impact factor: 3.603

6.  Time-to-treatment of diffuse large B-cell lymphoma in São Paulo.

Authors:  Flávia Dias Xavier; Debora Levy; Juliana Pereira
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.